Lidocaine vaginal gel - Juniper Pharmaceuticals

Drug Profile

Lidocaine vaginal gel - Juniper Pharmaceuticals

Alternative Names: 10% lidocaine gel - Juniper Pharmaceuticals; COL-1077

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia Laboratories
  • Developer Columbia Laboratories; Juniper Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Discontinued Dysmenorrhoea; Pain

Most Recent Events

  • 17 Aug 2016 Discontinued - Phase-II for Pain in USA (Vaginal)
  • 01 Jul 2016 Juniper Pharmaceuticals completes a phase II trial for Pain in USA (NCT02465320)
  • 16 Jun 2016 Pharmacokinetic and adverse events data from pharmacokinetic trials in healthy women volunteers released by Juniper Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top